Quart Barry D 4

What Happened

• Barry D. Quart, a director of Kiniksa Pharmaceuticals International, exercised 13,099 vested options on 2026-04-28 at an exercise price of $14.33 ($187,709 total cost) and sold the resulting 13,099 shares that same day in an open-market transaction for a weighted average price of $50.10, generating gross proceeds of $656,260. Net proceeds based on these figures are roughly $468,551 (does not account for taxes, fees or withholdings).

Key Details

• Transaction date: April 28, 2026.
• Option exercise: 13,099 shares exercised at $14.33 (total $187,709). (Code M = option exercise/conversion.)
• Open-market sale: 13,099 shares sold at a weighted average price of $50.10 (total $656,260). (Code S = sale.) Sales executed in multiple trades at prices between $50.00 and $50.725; reported price is a weighted average.
• Footnotes: Transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on Sept 11, 2025. The option exercised was fully vested and exercisable.
• Shares owned after the transaction: not stated in the provided filing.
• Filing timeliness: Reported period 2026-04-28 and filed 2026-04-29 — appears timely.

Context

• This was an exercise of vested options followed by an immediate sale of the shares (often described as a cashless or simultaneous sell following exercise). The reported sale was executed under a pre-established 10b5-1 plan, which specifies scheduled trades and can limit trading-date discretion. As with all insider sales, this is factual disclosure of transactions and should not be interpreted alone as a statement about the company's prospects.